Investor Relations

A FULLY INTEGRATED BIOPHARMACEUTICAL COMPANY WITH A ROBUST IMMUNO-ONCOLOGY PIPELINE AND PROVEN COMMERCIAL CAPABILITIES IN ONCOLOGY.

Coherus is a commercial-stage biopharmaceutical company focused on researching, developing, and commercializing innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline that will synergize with its proven commercial capabilities in oncology.

Coherus’ immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer. The foundational therapy in our immuno-oncology pipeline is LOQTORZI, a next-generation PD-1 inhibitor. Casdozokitug is a novel anti-IL-27 antibody currently being evaluated in two on-going clinical studies: a Phase 1/2 study in advanced solid tumors and a Phase 2 study in hepatocellular carcinoma. CHS-114 is a highly selective, competitively positioned, ADCC-enhanced anti-CCR8 antibody currently in a Phase 1 study in patients with advanced solid tumors.CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the novel pathway ILT4, with an IND accepted by the FDA in Q2 2024.

Coherus markets LOQTORZI® (toripalimab-tpzi), a next-generation PD-1 inhibitor, and UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta®.

Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.